Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

ABSTRACT: Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therapy and who are not candidates for targeted therapies. More therapeutic options are needed for the management of patients with NSCLC after failure of first-line chemotherapy. A PubMed search was performed for articles from January 2012 to May 2015 using the keywords NSCLC, antiangiogenic, immunotherapy, second-line, novel therapies and English language articles only. Relevant papers were reviewed; papers outside that period were considered on a case-by-case basis. A search of oncology congresses w

SUBMITTER: Manegold C 

PROVIDER: S-EPMC5729303 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature